BPC-157
BPC-157 is the go-to peptide for tendon, ligament, and gut-lining recovery, used by athletes and everyday injury patients to speed healing after strains, tears, and other soft-tissue injuries. It works by boosting blood flow and calming inflammation at the site of injury, backed by a large body of animal and lab research. It is one of the most widely used recovery peptides in this catalog, valued for supporting the body's own repair process after injury.
$75 / 10 mg vial
Dosing
Community reported
| Timeframe | Dosage | Frequency | Note |
|---|---|---|---|
| Weeks 1-2 | 200 mcg (0.2 mg) | once daily | Starting dose1 |
| Weeks 3-4 | 400 mcg (0.4 mg) | once daily | |
| Weeks 5-8+ | 600 mcg (0.6 mg) | once daily | Target/maintenance2 |
- Subcutaneous. Cycle length 8-12 weeks, optional extension to 16 weeks; no specific human maximum-safe-dose has been established in the cited literature.
- Community threads describe a lower everyday baseline of 250-500 mcg, up to 1 mg for stubborn injuries, somewhat below this site's stated 600 mcg ceiling; some users also report the low end awkward to measure on a standard syringe.
Batches on hand
Availability
30 vials on hand.
MKM-BPC10-26072630 vials
Full research
Evidence tier
Early human data only
One retrospective, uncontrolled, unblinded human case series (17 patients, 12 on BPC-157 alone) exists in the published literature, alongside an abandoned, unpublished Phase I safety and pharmacokinetics trial. The overwhelming majority of the evidence base, 35 of 36 studies in the most recent systematic review, is animal or in-vitro.
Original dosing schedule
The Dosing table above this section now shows a community- or vendor-sourced schedule (peptidedosages.com). The regulatory-label or clinical-trial dosing this entry was originally built on is kept here, unchanged, rather than removed.
Clinical trial
| Timeframe | Dosage | Frequency | Note |
|---|---|---|---|
| Single dose | 4 mg (in 2 mL) | single injection | Intra-articular1 |
- In some cases combined with 6 mg thymosin beta-4. This is a different administration route than the subcutaneous community schedule above and is not interchangeable with it.
Identity
| Full name | Body Protection Compound 157 (BPC-157) |
|---|---|
| Class | Synthetic pentadecapeptide, a partial sequence derived from human gastric juice protein BPC |
| Molecular weight | 1419.55 g/mol |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV) |
Mechanism of action
Plain language
BPC-157 is proposed to help tissue repair itself faster by improving blood flow to injured areas and calming local inflammation and oxidative stress. Essentially all of this evidence comes from cell and animal studies; the mechanism in humans is inferred, not directly demonstrated.
Technical
The literature most consistently implicates interaction with the nitric oxide system, including upregulation of endothelial nitric oxide synthase-derived nitric oxide and increased expression of VEGFR2 in models of ischemia, both proposed to drive angiogenesis. In tendon-explant models, BPC-157 has been reported to promote fibroblast outgrowth, survival, and migration, an effect attributed to activation of the FAK-paxillin signaling pathway. It has also been reported to upregulate antioxidant-response genes including heme oxygenase-1 and glutathione peroxidase 2. All of these mechanistic claims are proposed rather than established in humans; no human mechanistic, receptor-binding, or target-engagement study has been published.
Sources: Rasic-Markovic A, et, 2025, Chang CH, et, 2011
Why: Animal healing signal
Animal and cell studies report BPC-157 improving healing of tendon, ligament, muscle, bone, and gut tissue, proposed to work through nitric-oxide signaling and VEGFR2-driven angiogenesis, with fibroblast migration in tendon-explant models attributed to FAK-paxillin pathway activation. This evidence base is extensive, but it has not been replicated in a controlled human trial.
Sources: Rasic-Markovic A, et, 2025, Chang CH, et, 2011
Why: One human case series
The entire published human record for BPC-157 is a single retrospective, uncontrolled, unblinded case series of 17 patients, 12 of whom received BPC-157 alone. A systematic review found this was the only human study among 36 identified in orthopaedic and sports-medicine contexts; the remaining 35 were animal studies.
Sources: Lee E, Padgett, 2021, Vasireddi N, et, 2025
Why: No controlled safety data
FDA placed BPC-157 in a restricted compounding category in 2023 over immunogenicity, impurity, and limited safety-information concerns, and the most recent systematic review of the human literature found no clinical safety data at all. It is sold as an unregulated research chemical with no pharmaceutical quality oversight of manufacturing.
Sources: U.S. FDA. Bulk, 2023, Vasireddi N, et, 2025
What it’s used for
Human trials, not approved for this use
- The single published human clinical study is a retrospective, uncontrolled, unblinded chart review of intra-articular BPC-157 injection for chronic knee pain (17 patients, 12 on BPC-157 alone). Seven of the 12 patients on BPC-157 alone reported pain relief lasting more than six months, with no control group, no placebo arm, no blinding, and self-reported outcomes. A systematic review found this was 1 of 36 total studies identified on BPC-157 in orthopaedic and sports-medicine contexts; the other 35 were preclinical animal studies, and the review concluded all available clinical evidence is case-series or expert-opinion tier with no clinical safety data found.
Sources: Lee E, Padgett, 2021, Vasireddi N, et, 2025
Off-label / community use
- Widely used off-label and outside any regulatory framework in fitness, longevity, and injury-recovery communities for soft-tissue injury, tendon and ligament repair, gut and gastrointestinal symptoms, and general recovery. This use is anecdotal, self-reported, and not supported by controlled human data.
Pharmacokinetics
| Human pharmacokinetics, any route |
Not established No citable figure. No published human pharmacokinetic study exists for BPC-157 by any route; the field's own systematic reviews describe human PK data as absent or scanty. |
|---|---|
| Half-life (animal, intravenous, not human-translatable) |
Animal / in-vitro Under 30 minutes in rat and beagle dog; approximately 15.2 minutes in one rat study after intravenous dosing Sources: He L, Feng, 2022 |
| Bioavailability (animal, intramuscular) |
Animal / in-vitro Approximately 14-19% in rats; 45-51% in beagle dogs Sources: He L, Feng, 2022 |
| Time to peak concentration, Tmax (animal) |
Animal / in-vitro Approximately 3 minutes in rats; 6.3-8.7 minutes in dogs across dose-ranging studies Sources: He L, Feng, 2022 |
| Route and disposition (animal) |
Animal / in-vitro Studied intravenously and intramuscularly in rats and dogs; metabolized into small peptide fragments and free amino acids, excreted mainly via urine and bile, with poor blood-brain-barrier penetration. No human PK study by any route has been published. Sources: He L, Feng, 2022 |
Reconstitution
| Vial strength | Most frequently 5 mg lyophilized powder per vial, also sold in 2 mg and 10 mg strengths |
|---|---|
| Diluent | Bacteriostatic water |
| Diluent volume | 2 mL (common vendor convention); an alternative 3 mL reconstitution is also described |
| Concentration | 2.5 mg/mL (5 mg vial in 2 mL); approximately 1.67 mg/mL (5 mg vial in 3 mL) |
Worked example
On a U-100 insulin syringe, 20 units equals 500 mcg and 10 units equals 250 mcg at 2.5 mg/mL. With the 3 mL reconstitution, each unit delivers approximately 16.7 mcg.
Sources: Multiple commercial vendor
Dose calculator
Enter a vial strength, diluent volume, and desired dose to see the resulting concentration, dose volume, and units on a standard U-100 insulin syringe. Nothing entered here is saved, stored, or sent anywhere – the calculation runs only in your browser.
Enable JavaScript to use the interactive calculator. The worked example above already shows a complete calculation for this compound.
Storage and post-reconstitution stability
Unopened storage
Vendors describe lyophilized, unreconstituted BPC-157 as stable refrigerated or frozen, protected from light, prior to reconstitution.
Post-reconstitution stability – Vendor claim
Approximately 28-30 days refrigerated. 2-8C
No citable figure. This figure comes from vendor guidance rather than a published stability study and should be treated as unverified.
Safety
Notable risks
- FDA placed BPC-157 in Category 2 of its 503A bulk drug substances list in September 2023, based on potential immunogenicity, peptide-related impurity and characterization concerns, and the absence of adequate safety information for the proposed routes of administration. FDA has stated there is no legal basis for compounding pharmacies to use BPC-157 in compounded medications.
Sources: U.S. FDA. Bulk, 2023
- BPC-157 is not scheduled as a controlled substance in the United States but is prohibited at all times in competitive sport under the World Anti-Doping Agency Prohibited List, and is sold almost exclusively as an unregulated research chemical, with manufacturing not subject to pharmaceutical quality oversight.
Sources: USADA. BPC-157: Experimental
- No controlled human safety data exist. Preclinical toxicology in rats and beagle dogs, single-dose intramuscular up to 20 mg/kg in rats and 10 mg/kg in dogs, and repeated 28-day dosing up to 4 mg/kg/day in rats and 2 mg/kg/day in dogs, reported no deaths and no gross abnormalities, but a systematic review of the human literature found no clinical safety data at all.
- BPC-157's pro-angiogenic activity, VEGFR2 upregulation, is flagged in the literature as a theoretical tumor-growth concern, though mouse cancer-implantation models did not show a marked reduction in tumor size with BPC-157 administration, and did not report data showing it accelerates tumor growth either. A theoretical nitric-oxide-mediated mitochondrial toxicity concern and a theoretical proline-metabolite oxidative-stress concern have also been raised. All are described as mechanistic extrapolations, not observed clinical adverse events.
Sources: Rasic-Markovic A, et, 2025
Sources
- Rasic-Markovic A, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide, Literature and Patent Review. Pharmaceuticals (Basel) (2025)
- U.S. FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, Category 2 update, September 29, 2023 (FDA.gov guidance/advisory-committee-briefing page, not a prescribing label or Federal Register notice) (2023)
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (2011)
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med (2021)
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J (2025)
- He L, Feng D, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol (2022)
- USADA. BPC-157: Experimental Peptide Creates Risk for Athletes (anti-doping authority advisory page, not an FDA or EMA prescribing document)
- Multiple commercial vendor and dosing-guide pages (e.g. peptidedosages.com, formblends.com, thepeptidecatalog.com, biogenixpeptides.com), cited only to describe commercially sold vial strengths and vendor-stated reconstitution and dosing convention, not as evidence for any efficacy or safety claim
- peptidedosages.com, BPC-157 5 mg vial dosage protocol
This is a research and educational reference, not medical advice. Nothing on this site is a recommendation to use any compound.